Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Trial Profile

Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2015

At a glance

  • Drugs Rituximab (Primary) ; Cladribine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 03 Oct 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top